Carbon footprint of industry-sponsored late-stage clinical trials

OBJECTIVES: To quantify the carbon footprint from a sample of pharma industry sponsored phase III trials. To develop an approach that can readily be applied to future trials by AstraZeneca and other trial sponsors. DESIGN: Life cycle assessment including all the sources of carbon emissions associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackillop, Neil, Shah, Jayesh, Collins, Michael, Costelloe, Thomas, Öhman, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445340/
https://www.ncbi.nlm.nih.gov/pubmed/37604634
http://dx.doi.org/10.1136/bmjopen-2023-072491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445340/
https://www.ncbi.nlm.nih.gov/pubmed/37604634
http://dx.doi.org/10.1136/bmjopen-2023-072491

Ejemplares similares